Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Free Report) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 845,600 shares, a decrease of 28.3% from the February 13th total of 1,180,000 shares. Based on an average trading volume of 325,600 shares, the short-interest ratio is presently 2.6 days. Currently, 6.2% of the company’s stock are sold short.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on SRTS shares. HC Wainwright boosted their price target on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Lake Street Capital decreased their price target on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th.
Get Our Latest Stock Report on SRTS
Hedge Funds Weigh In On Sensus Healthcare
Sensus Healthcare Trading Up 1.9 %
Shares of Sensus Healthcare stock traded up $0.09 during trading on Monday, hitting $4.74. The stock had a trading volume of 21,072 shares, compared to its average volume of 344,450. The firm has a market cap of $78.19 million, a price-to-earnings ratio of 11.85 and a beta of 1.28. Sensus Healthcare has a 12 month low of $3.09 and a 12 month high of $9.33. The business’s 50-day moving average is $6.03 and its 200 day moving average is $6.65.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Stories
- Five stocks we like better than Sensus Healthcare
- 3 Dividend Kings To Consider
- Super Micro’s International Presence Makes It a Winning Stock
- What Investors Need to Know About Upcoming IPOs
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- The 3 Best Fintech Stocks to Buy Now
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.